Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Nivolumab in Resected NSCLC with MRD
NCT03770299Phase 2Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2021
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Planned start Jan 2021; status: withdrawn.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03770299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03770299.